We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Weekly CAF Chemotherapy for Advanced Breast Cancer Patients.
- Authors
Hwang, Wei-Shou; Hsiung, Chao A.; Ko, Wann-Sheng; Wang, Chang-Chung; Chang, Jang-Yang; Lai, Gi-Ming; Hsieh, Ruey-Kuen; Tsao, Chao-Jung; Chen, Li-Tzong; Law, Chi-Kong; Cheng, Ann-Lii; Fan, Sheng F.; Tzeng, Cheng-Hwai; Chiou, Tzeon-Jye; Whang-Peng, Jacqueline
- Abstract
In a prospective phase II study, 102 women with advanced breast cancer were treated with low doses of cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) at weekly intervals by intravenous injection. Seventy-five patients were evaluable for treatment response and the overall response rate was 52% (95% confidence interval, 41-63%). Of the evaluable patients, 15% had complete response and 37% had partial response. The median survival after therapy was 15.6 months, the median time to progression was 6.8 months and the median duration of response was 9.1 months. The main toxicities were mild vomiting and moderate myelosuppression. There was only 1 patient who experienced heart failure. Weekly CAF appears to have an efficacy with tolerable side effects comparable to standard CAF with an every-3-week schedule. Copyright © 1997 S. Karger AG, Basel
- Publication
Oncology, 1997, Vol 54, Issue 4, p293
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000227706